NR3C1 and cancer: In this phase 1b study of ORIC-101 in patients with advanced solid tumors, we tested the hypothesis that taxane-resistant cancers could potentially be resensitized to nab-paclitaxel by concurrent administration of a highly potent GR antagonist, ORIC-101.